Skip to main content
Signal8

Aker Christopher Ray

SEC insider (Form 3/4/5 filer). CIK 0001762611. Sr. VP & General Counsel at Regulus Therapeutics Inc. (RGLS). 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 25, 2025. Located in SAN DIEGO, CA.

Companies Aker Christopher Ray has filed insider reports for

  • Regulus Therapeutics Inc. (RGLS): Officer, Sr. VP & General Counsel
Aker Christopher Ray profile photo

Aker Christopher Ray

CIK: 0001762611

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Regulus Therapeutics Inc. logo
RGLS

Regulus Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jun 25, 2025
    Tender Offer
    Direct
    60.8K shares-
  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jun 25, 2025
    Disposition
    Direct
    83.1K shares-
  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jan 30, 2025
    Award

    Stock Option (Right to Buy)

    Direct
    487.5K shares-
  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jan 14, 2025
    Sale
    Direct
    5.1K shares at avg. $1.26$6K
  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jan 13, 2025
    Sale
    Direct
    38.5K shares at avg. $1.26$49K
  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jan 9, 2025
    Award
    Direct
    66.6K shares at avg. $1.36$91K
  • Regulus Therapeutics Inc. logo
    RGLS

    Regulus Therapeutics Inc.

    Jan 9, 2025
    Award
    Direct
    17.5K shares at avg. $1.30$23K

1-7 of 7